Conference abstract · 26 Jun 2017
Conference abstractPublished 26 Jun 2017
Bioequivalence inspection
President Medical Services in Macleod’s Pharmaceuticals Limited
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Bioequivalence study is conducted on healthy volunteer/patient to compare pharmacokinetic parameter of test product and reference product. Generic company conducting/sponsoring the study should be aware of risks of rejection and non-compliance. Methodology & Theoretical Orientation: Current topic will cover list of inspection findings from various regulatory agencies like US, EU and WHO and How to be ready for unannounced inspection, Presentation will discuss current inspection trends and queries asked during dossier assessment. Conclusion & Significance: This presentation will critically review inspector and assessors expectation on Bioequivalence studies. Understanding such expectation will help for early and successful approval of the product.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 29 Aug 2016
Audits and Inspections - bioavailability and bioequivalence studies
Perspective · 28 Mar 2024
Forensic Death Investigation Involves the Mysteries of Mortality: Inspect Forensic Death Investigation
Short communication · 30 May 2022
Consolidating Detached Inspecting With Poisonousness Testing To Assess Potential Ecotoxicological Impacts of Drugs in Wastewater-Influenced Waterways
Conference abstract · 2018
Pharmaceuticals pharmacovigilance system compliance: Are you ready for authorities inspection?
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ashish A Mungantiwar”
